Analysts Set United Therapeutics Co. (NASDAQ:UTHR) Price Target at $294.25

Shares of United Therapeutics Co. (NASDAQ:UTHR) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $294.25.

A number of equities analysts have commented on the company. HC Wainwright restated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $213.00 to $215.00 in a research note on Monday, February 12th. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Wedbush reaffirmed an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th.

United Therapeutics Price Performance

United Therapeutics stock opened at $233.85 on Wednesday. The stock’s fifty day moving average price is $233.74 and its two-hundred day moving average price is $228.81. United Therapeutics has a one year low of $204.44 and a one year high of $261.54. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. The firm has a market cap of $11.00 billion, a PE ratio of 11.79 and a beta of 0.52.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The firm had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. During the same quarter last year, the company earned $2.67 EPS. The company’s revenue was up 25.1% on a year-over-year basis. As a group, research analysts expect that United Therapeutics will post 23.45 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,756.70. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,756.70. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Nilda Mesa sold 325 shares of the firm’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total value of $77,285.00. Following the sale, the director now directly owns 5,373 shares in the company, valued at approximately $1,277,699.40. The disclosure for this sale can be found here. Insiders have sold a total of 136,990 shares of company stock valued at $32,239,641 in the last 90 days. 12.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rise Advisors LLC acquired a new position in United Therapeutics during the 1st quarter worth about $32,000. GAMMA Investing LLC acquired a new position in United Therapeutics during the 4th quarter worth about $43,000. C M Bidwell & Associates Ltd. acquired a new position in United Therapeutics during the 3rd quarter worth about $91,000. Janiczek Wealth Management LLC lifted its holdings in United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after buying an additional 84 shares during the period. Finally, Blue Trust Inc. lifted its holdings in United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after buying an additional 46 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.